Stock market today: S&P 500 hits fresh record close on stronger economic growth
SAN FRANCISCO—Vanina de Verneuil, Executive Vice President and General Counsel at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 7,373 shares of the company’s common stock. The sales, disclosed in a Form 4 filing with the Securities and Exchange Commission, were conducted on February 26, 2025, and amounted to a total value of $67,402. The shares were sold at a weighted average price of $9.1418, with individual transaction prices ranging from $9.03 to $9.30. The $1.19 billion market cap biotech company has shown strong momentum this year, with shares up over 25% year-to-date according to InvestingPro data.
Following these transactions, de Verneuil holds 79,460 shares directly. The sales were made under a pre-established Rule 10b5-1 trading plan adopted on August 5, 2024. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional key insights available to subscribers. Access the comprehensive Pro Research Report covering VIR and 1,400+ other US stocks to make more informed investment decisions.
In other recent news, Vir Biotechnology Inc . reported its fourth-quarter 2024 earnings, surpassing market expectations with a narrower-than-anticipated loss and significantly higher revenue. The company posted an earnings per share (EPS) of -$0.76, beating the forecasted -$0.87, while revenue reached $12.37 million, exceeding the expected $8.14 million. Vir Biotech has also made notable strides in cost management, with research and development expenses drastically reduced to $57 million from $580 million in 2023, and general and administrative expenses down by 32% to $119 million. Additionally, Vir Biotech is accelerating its ECLIPSE Phase 3 program for hepatitis delta and advancing its PSMA-targeted T cell engager program. The company aims to initiate a Phase 1 study for its EGFR-targeted therapy and seek partnerships for its hepatitis B program. These recent developments reflect the company’s strategic focus on high-potential programs and effective cost management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.